CTIS.eu › Conditions › Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is a rare disorder confined to the cerebral parenchyma, leptomeninges, eyes or spinal cord. It accounts for 4 to 6% of all Non- Hodgkin's lymphomas and for 3 to 4% of all primary brain tumors. Incidence of PCNSL has increased over the past 30 years, particularly in immunocompetent individuals. With a median survival of 3 months in untreated individuals, prognosis of PCNSL resembles that of systemic high-grade NHL

Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is a rare disorder confined to the cerebral parenchyma, leptomeninges, eyes or spinal cord. It accounts for 4 to 6% of all Non- Hodgkin's lymphomas and for 3 to 4% of all primary brain tumors. Incidence of PCNSL has increased over the past 30 years, particularly in immunocompetent individuals. With a median survival of 3 months in untreated individuals, prognosis of PCNSL resembles that of systemic high-grade NHL

1 total trials

Filter these 1 trials by phase, country, sponsor and more.

Open in Search →

Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Recruitment ended

2024-514473-21-00 5 2021-06-21

Showing 1–1 of 1 trials